ClinicalTrials.gg
CompletedNCT06468722Updated Jun 25, 2024

Fat Oxidation Capacity in Patients With Post Covid-19 Syndrome

An observational study in Post-COVID-19 Syndrome and Long-COVID-19 Syndrome, sponsored by University of Witten/Herdecke. Completed at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-06-25.

Sponsored by University of Witten/Herdecke · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
187
Ages
18 Years and older
Sex
All
01

Study summary

Post-COVID-19 Syndrome (PCS) is characterized by symptoms, including fatigue, reduced physical performance, dyspnea, cognitive impairment, and psychological distress. The mechanisms underlying the onset and severity of PCS point to mitochondrial dysfunction as significant contributor. This study examined fat oxidation as a function of mitochondrial capacity during exercise.

Read the detailed description

Post-COVID-19 Syndrome (PCS), also known as post-acute sequelae of COVID-19, manifests following an acute infection with the SARS-CoV-2 virus (COVID-19 infection). PCS is characterized by the persistence of symptoms beyond 12 weeks from the onset of infection and/or the emergence of new symptoms within this time. Although recent guidelines offer specific criteria to diagnose PCS, ambiguity persists due to the complex nature of its symptomatology and the lack of definitive diagnostic tools. PCS is a multisystemic disorder characterized by symptoms such as (chronic) fatigue, diminished physical performance, muscular weakness and pain, dyspnea, cognitive impairments and alterations of the autonomous nervous system, as well as mental and psychological distress. The severity of symptoms varies widely among patients, from mild impairment to significant restrictions in daily activities, potentially leading to partial or complete incapacity to work. Of note, the severity of the acute infection does not predict the onset or severity of PCS. Even though many patients experience gradual recovery without specific treatment, there is a substantial need for effective medical rehabilitation, especially for those with persistent PCS. To this respect, exercise-based programs have been shown to induce significantly exercise capacity as well as higher quality of life, reduced fatigue, and less depression. Despite ongoing investigations, the mechanisms contributing to the onset and severity of PCS remain largely unknown. Factors may include endothelial dysfunction and detrimental effects on the microvasculature, as well as a "cytokine storm" associated with excessive oxidative stress and subsequent mitochondrial dysfunction which has emerged as a significant potential contributor.

Notably, detrimental effects on mitochondrial function have been described as a result of severe acute infections triggering an excessive immune response, systemic inflammation and oxidative stress. Recent studies suggested that impaired mitochondrial function in PCS may be associated with impaired fatty acid oxidation (FatOx) which can be identified using cardiopulmonary exercise testing (CPET). Currently, the number of PCS patients characterized for changes in FatOx using CPET is low and associations with signs and symptoms of PCS such as fatigue have not been reported in detail. Moreover, reports on the potential of exercise-based rehabilitation to restore FatOx capacity in PCS are not available. Thus, the current study aimed to investigate if analysis of breath-by-breath spirometric data followed by an estimation of individual FatOx capacity can be used for the stratification of PCS patients. The investigators hypothesized that a lower FatOx potential would be associated with PCS-specific signs and symptoms such as mental and physical fatigue. In addition, the investigators sought to analyze if exercise-based rehabilitation would be effective in restoring PCS patients' FatOx capacity as a sign of improved mitochondrial function.

02

Conditions studied

  • Post-COVID-19 Syndrome
  • Long-COVID-19 Syndrome

Keywords

  • SARS-CoV-2
  • Long-COVID-19
  • Exercise-based Rehabilitation
  • Mitochondrial Dysfunction
  • Fatigue
03

In context

Post-Acute COVID-19 Syndrome

604 studies on the registry are indexed under Post-Acute COVID-19 Syndrome; 201 are open to participants now.

This study's enrollment of 187 is above the median of 150 across 173 observational studies indexed under Post-Acute COVID-19 Syndrome.

Browse Post-Acute COVID-19 Syndrome studies →

Lead sponsor

University of Witten/Herdecke is the lead sponsor of 40 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with Post-COVID-19 syndrome who are referred to Clinic Königsfeld for inpatient medical rehabilitation and who are willing to participate in the study and give their written informed consent. Inclusion criteria were a history of (at least one) COVID-19 infection (positive PCR test at the time of infection), and ongoing or newly expressed performance deficits lasting for at least 3 months prior to recruitment.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • a history of (at least one) Covid-19 infection
  • ongoing or newly expressed performance deficits lasting for at least 3 months prior to recruitment
  • referral to inpatient rehabilitation
  • signed

Exclusion criteria

Exclusion Criteria:

  • unstable condition
  • incapable of understanding study information
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
187 participants (actual)
Patient registry
No

Groups and cohorts

  • Post-Covid-19 Syndrome Patients

    Behavioral: Exercise-based rehabilitation

Interventions

  • BehavioralExercise-based rehabilitation

    Patients performed regular physical exercise during inpatient rehabilitation

06

What researchers measure

Primary outcomes

  1. Change in Fat Oxidation Rate

    Fat oxidation will be assessed by breath-by-breath spiroergometry

    Time frame: Baseline and week 4 (i. e. before discharge)

Secondary outcomes

  1. Change in Carbohydrate Oxidation Rate

    Carbohydrate oxidation rate will be assessed by breath-by-breath spirometry

    Time frame: Baseline and week 4 (i. e. before discharge)

  2. Change in Fatigue

    Fatigue will be assessed using the "The Multidimensional Fatigue Inventory (MFI20)"

    Time frame: Baseline and week 4 (i. e. before discharge)

07

Study locations

1 site
  • Clinic Königsfeld
    Ennepetal, NRW 58256, Germany
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 25, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06468722
Lead sponsor
University of Witten/Herdecke
Collaborators
Institut für Rehabilitationsforschung Norderney
Responsible party
Sponsor
First posted
Jun 21, 2024
Start date
Apr 1, 2021
Primary completion
Jun 30, 2023
Completion
May 21, 2024
Last update
Jun 25, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion